mortality/aging
N |
• mice do not become sick enough to require euthanasia unlike Zfp36tm1.2Xen homozygotes
|
immune system
• in some mice
• in LPS-treated mice
|
• modest at 3 to 4 months in female mice
|
• 110 fold in LPS-treated mice
|
• in some mice
|
• widespread inflammatory cell infiltrates in liver, kidney, and lung in LPS-treated mice
|
• LPS-treated mice exhibit dramatic signs of endotoxemia (lethargy, tachypnea, piloerection and decreased body temperature); elevated TNF serum levels; enlarged spleens and dilated small intestines, with widespread inflammatory cell infiltrates in liver, kidney, and lung; scattered foci of hepatic necrosis, glomerular hypercellularity, and pulmonary alveolitis; and 5-fold increase in serum alanine aminotransferase, a 2.2-fold increase in blood urea nitrogen, and a 3-fold increase in lactate dehydrogenase compared with control mice
|
• mild interphalangeal arthritis and inflammation in 1 of 4 mice
|
alveolitis
(
J:188677
)
• in LPS-treated mice
|
muscle
• mild inflammation and fibrosis in 3 of 4 mice at 8 months
|
homeostasis/metabolism
• 2.2-fold in LPS-treated mice
|
• 110 fold in LPS-treated mice
|
• 5-fold in LPS-treated mice
|
• 3-fold in LPS-treated mice
|
• dramatic in LPS-treated mice
|
behavior/neurological
• dramatic in LPS-treated mice
|
respiratory system
alveolitis
(
J:188677
)
• in LPS-treated mice
|
cardiovascular system
• mild inflammation and fibrosis in 3 of 4 mice at 8 months
|
growth/size/body
• at 6.5 months in female mice
• at 9 months in male mice
|
• in some mice
• in LPS-treated mice
|
• modest at 3 to 4 months in female mice
|
digestive/alimentary system
• dilated in LPS-treated mice
|
liver/biliary system
• scattered foci of hepatic necrosis in LPS-treated mice
|
hematopoietic system
• in some mice
• in LPS-treated mice
|
• modest at 3 to 4 months in female mice
|
renal/urinary system
• glomerular hypercellularity in LPS-treated mice
|
skeleton
• mild interphalangeal arthritis and inflammation in 1 of 4 mice
|